تعديل

jeudi 7 janvier 2016

J&J signs deal with Chinese company for hepatitis B drug

(Reuters) - Johnson & Johnson on Thursday said it licensed rights from a Chinese drugmaker to drugs that spur the immune system to help fight diseases, which it hopes will become a key part of a cure for chronic hepatitis B.











http://ift.tt/22MTj4G

from Reuters: Health News
via animenewspro

Aucun commentaire:

Enregistrer un commentaire